86. Pulmonary arterial hypertension Clinical trials / Disease details

Clinical trials : 1,181 / Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04266197 (ClinicalTrials.gov)	September 25, 2020	22/1/2020	Effects of RT234 on Exercise Parameters Accessed by CPET in Subjects With PAH	A Phase 2, Open-label, Single Dose Study to Evaluated the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects With Pulmonary Arterial Hypertension (PAH)	Pulmonary Arterial Hypertension	Combination Product: Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)	Respira Therapeutics, Inc.	Precision For Medicine;Argint International	Recruiting	18 Years	80 Years	All	40	Phase 2	United States;Serbia
2	NCT03833323 (ClinicalTrials.gov)	August 1, 2020	5/2/2019	Implantable System for Remodulin Post-Approval Study	Implantable System for Remodulin Post-Approval Study	Pulmonary Arterial Hypertension	Combination Product: Implantable System for Remodulin (treprostinil)	Medtronic Cardiac Rhythm and Heart Failure	United Therapeutics	Withdrawn	22 Years	N/A	All	0		NULL
3	NCT04309838 (ClinicalTrials.gov)	March 2020	20/2/2020	Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension	LENUS Pro® Study (LPS-II) - Observation Study With Implantable Medication Pump for Intravenous REMODULIN® (Treprostinil) Therapy in Patients With Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension;PAH	Combination Product: Treprostinil via implanted pump	University Medicine Greifswald	OMT GmbH & Co. KG	Not yet recruiting	18 Years	N/A	All	30		Germany